Advertisement

Topics

PubMed Journals Articles About "Immunotherapy Could Offer Hope Some With Aggressive Prostate" RSS

22:48 EDT 25th March 2019 | BioPortfolio

Immunotherapy Could Offer Hope Some With Aggressive Prostate PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Immunotherapy Could Offer Hope Some With Aggressive Prostate articles that have been published worldwide.

More Information about "Immunotherapy Could Offer Hope Some With Aggressive Prostate" on BioPortfolio

We have published hundreds of Immunotherapy Could Offer Hope Some With Aggressive Prostate news stories on BioPortfolio along with dozens of Immunotherapy Could Offer Hope Some With Aggressive Prostate Clinical Trials and PubMed Articles about Immunotherapy Could Offer Hope Some With Aggressive Prostate for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunotherapy Could Offer Hope Some With Aggressive Prostate Companies in our database. You can also find out about relevant Immunotherapy Could Offer Hope Some With Aggressive Prostate Drugs and Medications on this site too.

Showing "Immunotherapy Could Offer Hope Some with Aggressive Prostate" PubMed Articles 1–25 of 5,400+

Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.

Immunotherapy is rapidly transforming cancer care across a range of tumor types. Although Sipuleucel-T represented the first successful vaccine for the treatment of established cancer, other immunotherapeutic approaches for prostate cancer such as checkpoint inhibitors have been relatively disappointing to date. However, significant promise is on the horizon as there is a wide array trials evaluating immunotherapy in prostate cancer patients. These include both immune checkpoint inhibitors and antigen-speci...


A short peptide reverses the aggressive phenotype of prostate cancer cells.

Previous studies have demonstrated that fibroblast growth factor 8b (FGF8b) is up-regulated in a large proportion of prostate cancer patients, and plays a key role in the aggressive progress of prostate cancer. Herein, we investigated the effects of a short peptide derived from the gN helix domain of FGF8b on the metastatic behaviors of prostate cancer cells. The results demonstrated that the synthetic peptide might reverse the effects of FGF8b on cell proliferation, migration and invasion by suppressing th...

High miR-182 Levels Associate with Low-Risk Prostate Cancer.

A subset of men with prostate cancer develops aggressive disease. We sought to determine if miR-182, a microRNA with reported oncogenic functions in prostate, associates with biochemical recurrence and aggressive disease. Prostate epithelial miR-182 expression was quantified via in situ hybridization of two prostate tissue microarrays and by laser-capture microdissection of prostate epithelium. MiR-182 was significantly higher in cancer epithelium than adjacent benign epithelium (P < 0.0001). The ratio of c...


Immunotherapy for the treatment of prostate cancer-a comeback?

Prostate cancer (PCA) seems to be more of an immunologic desert than other tumor entities. It is striking that only rarely does prostate cancer show abundant immune cells and a proimmunogenic microenvironment.

Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer.

Aggressive variant transformation in metastatic castration-resistant prostate cancer (mCRPC) represents an under-recognized phenomenon. There is an urgent need for non-invasive biomarkers to detect these variants and identify treatment alternatives.

How Would MRI-Targeted Prostate Biopsy Alter Radiation Therapy Approaches in Treating Prostate Cancer?

To determine if MRI/ultrasound fusion-targeted prostate biopsy (TB) would lead to increased recommendations of aggressive radiotherapy treatments for higher risk prostate cancer compared to systematic biopsy (SB) results.

Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.

Despite the success of T cell checkpoint blockade against melanoma, many "cold" tumors such as prostate cancer remain unresponsive. We find that hypoxic zones are prevalent across pre-clinical prostate cancer and resist T cell infiltration even in the context of CTLA-4 and PD-1 blockade. We show that the hypoxia-activated prodrug TH-302 reduces or eliminates hypoxia in these tumors. Combination therapy with this hypoxia-prodrug and checkpoint blockade cooperate to cure more than 80% of TRAMP-C2 prostate tum...

ANO7 is associated with aggressive prostate cancer.

Prostate cancer is one of the most common and heritable human cancers. Our aim was to find germline biomarkers that can predict disease outcome. We previously detected predisposing signals at 2q37, the location of the prostate specific ANO7 gene.

Oncology, what's new in 2018.

The year 2018 has been incredibly prolific regarding novelties. Several studies have given impressive results and offer new anticancer perspectives. Immunotherapy is gaining more and more place defining a new standard of care for different types of cancer. In parallel with a new approach combining immunotherapy and chemotherapy that is emerging, new forms of adoptive immunotherapy are on the path of approval by regulatory authorities. At the decision-making level, a large somatic genetic analysis is becomin...

Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.

Pancreatic ductal adenocarcinoma (PDAC) continues to be one of the most aggressive and lethal diseases in the world. The success of immunotherapy in other types of malignancy has led to further trials to understand better the role of immunotherapy in PDAC. However, initial studies with immunotherapy, namely, the checkpoint inhibitors, in PDAC have not been met with the same outcomes. The purpose of this review is to identify and discuss the various resistance mechanisms of PDAC to immunotherapy (pancreatic ...

Mutations in GAS5 affect the transformation from benign prostate proliferation to aggressive prostate cancer by affecting the transcription efficiency of GAS5.

In this study, we aimed to explore the effects of GAS5 single-nucleotide polymorphisms (SNPs) on GAS5 expression. And the signaling pathways underlying the function of GAS5 during the pathogenesis of prostate cancer (PC) were clarified.

Comparison of F-Choline PET/CT and MRI functional parameters in prostate cancer.

F-Choline (FCH) uptake parameters are strong indicators of aggressive disease in prostate cancer. Functional parameters derived by magnetic resonance imaging (MRI) are also correlated to aggressive disease. The aim of this work was to evaluate the relationship between metabolic parameters derived by FCH PET/CT and functional parameters derived by MRI.

Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.

Age at prostate cancer (PCa) diagnosis has been positively associated with PCa-specific mortality, and for men on active surveillance (AS), a higher risk of biopsy grade reclassification (BGR) to Gleason score ≥3+4 (grade group [GG]≥2); however, the association between age and BGR to an aggressive phenotype (Gleason score ≥4+3 [GG≥3]) has not been explored.

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.

Prostate cancer is the third leading cause of cancer-related death in men in the United States. Although serious, most of these diagnoses are not terminal. Inherited risk for prostate cancer is associated with aggressive disease and poorer outcomes, indicating a critical need for increased genetic screening to identify disease-causing variants that can pinpoint individuals at increased risk for metastatic castration-resistant prostate cancer.

The Nucleoporin POM121 Enhances Prostate Cancer Aggressiveness.

POM121 is upregulated in aggressive and lethal prostate cancers and promotes tumor growth .

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Immunotherapy has been less successful in treating prostate cancer than other solid tumors. We sought to better understand the immune landscape in prostate cancer and identify immune-related biomarkers and potential therapeutic targets.

How AI Is Optimizing the Detection and Management of Prostate Cancer.

Annually, approximately 20 million men are prostate-specific-antigen screened, and 1.3 million undergo an invasive biopsy to diagnose roughly 200,000 new cases, 50% of which end up being indolent. Approximately 30,000 men die of prostate cancer (PCa) yearly. Importantly, an estimated US$8 billion is spent on unnecessary biopsies. Thus, an integrative analysis and predictive model of prognosis is needed to help identify only lethal and aggressive forms of the disease.

Dietary patterns based on the Mediterranean diet and DASH diet are inversely associated with high aggressive prostate cancer in PCaP.

Several foods and nutrients have been linked to the development of prostate cancer, but the association between healthy dietary patterns and prostate cancer aggressiveness is less studied. The aim of this study was to evaluate the relationship between the Mediterranean diet (MED) and Dietary Approaches to Stop Hypertension (DASH) diet scores and prostate cancer aggressiveness by race.

DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.

Failure of effective DNA damage repair is a hallmark of cancer, but was previously underappreciated as a driver of aggressive prostate cancer. However, recent international sequencing efforts have revealed that both germline and somatic alterations within the homologous recombination and mismatch repair pathways are relatively common in lethal metastatic disease. BRCA2 gene alterations are particularly prevalent and are linked to poor prognosis as well as poor responses to systemic therapy for castration-re...

The modern treatment of metastatic castration-resistant prostate cancer.

The basic therapy of metastatic prostate carcinoma is androgen deprivation therapy. Unfortunately, almost all patients develop resistance to treatment that leads to castration-resistant prostate cancer. From 2010, 6 new active substances were registered for the treatment of metastatic castration-resistant prostate cancer, which dramatically improved the overall survival of patients. Two of these are treatments for the androgenic axis, the other drugs or therapeutic methods are immunotherapy, chemotherapy, i...

Transformation of adenocarcinoma of prostate to squamous cell carcinoma following hormonal treatment: A case report and review of the literature.

Squamous cell carcinoma (SCC) of the prostate is a rare tumor with aggressive nature. This type of tumor has a poor response to conventional treatment and results in poor prognosis. Squamous differentiation or metaplasia may arise subsequent to endocrine or radiation treatment, but it is very rare. To date, a few cases have been reported in the literature. Due to its rarity, the radiologic findings of SCC of the prostate are not well established. We describe a case of SCC of the prostate developing in a pat...

Immunotherapy for genitourinary tumors.

The present review provides an update about the major achievements and recent advances of immunotherapy in renal cell carcinoma, urothelial carcinoma, and prostate cancer. Although the treatment strategy for renal cell carcinoma and urothelial carcinoma includes traditional cancer immunotherapies, such as interleukin-2 and interferon-alfa, the clinical outcomes of these therapies are unsatisfactory. In recent years, the development of immune checkpoint inhibitors has drastically changed the treatment strate...

PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilizing MRI data to target tumor and benign tissue in fresh radical prostatectomy specimens.

Over one million men are diagnosed with prostate cancer each year worldwide, with a wide range of research programs requiring access to patient tissue samples for development of improved diagnoses and treatments. Random sampling of prostate tissue is sufficient for certain research studies, however there is a growing research need to target areas of aggressive tumor as fresh tissue. Here we set out to develop a new pathway "PEOPLE: PatiEnt prOstate samPLes for rEsearch" to collect high quality fresh tissue ...

Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma.

Metastatic urothelial cancer is an aggressive disease associated with a poor prognosis. In the first-line setting, platinum-based chemotherapy is the standard of care but resistance rapidly occurs. After failure of platinum-based therapy and in cisplatin-ineligible patients, therapeutic options are limited. Malignant cells evolve mechanisms to evade immune recognition, including the expression of cell-surface molecules, named immune checkpoints, on tumor and tumor-specific lymphocytes. Immunotherapy, by tar...

Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8 tumor-associated lymphocytes and poor prognosis in prostate cancer.

To investigate immune profile consisting of stromal PD-L1 expression, inhibitory or non-T-cell inflamed tumor microenvironment that may predict response to anti-PD-L1/PD-1 immunotherapy in prostate cancer, we validated the specificity of a PD-L1 monoclonal antibody (E1L3N) and identified PD-L1 specific expression in prostatic stromal nerve cells. PD-L1 expression was analyzed in 73 primary prostate cancers and 7 castration-resistant prostate cancers (CRPC) by IHC and resulting data from primary prostate can...


Advertisement
Quick Search
Advertisement
Advertisement